Obesity and Fat Metabolism in Human Immunodeficiency Virus–Infected Individuals: Immunopathogenic Mechanisms and Clinical Implications. (20th March 2019)

• Record Type: Journal Article
• Authors: Godfrey, Catherine; Bremer, Andrew; Alba, Diana; Apovian, Caroline; Koethe, John R; Koliwad, Suneil; Lewis, Dorothy; Lo, Janet; McComsey, Grace A; Eckard, Allison; Srinivasa, Suman; Trevillyan, Janine; Palmer, Clovis; Grinspoon, Steven
• Is Part Of: Journal of infectious diseases. Volume 220:Number 3(2019)
• Page Start: 420
• Page End: 431
• Publication Date: 2019-03-20
• Subjects: HIV -- obesity -- viral proteins -- inflammation -- metabolism; Communicable diseases -- Periodicals; Diseases -- Causes and theories of causation -- Periodicals; Medicine -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.9
• DOI: 10.1093/infdis/jiz118
• Languages: English
• ISSNs: 0022-1899

Abstract

Abstract: Metabolic complications relating to complex effects of viral and immune-mediated mechanisms are now a focus of clinical care among persons living with human immunodeficiency virus (PLHIV), and obesity is emerging as a critical problem. To address knowledge gaps, the US National Institutes of Health sponsored a symposium in May 2018 entitled "Obesity and Fat Metabolism in HIV-infected Individuals." Mechanisms relating to adipose dysfunction and fibrosis, immune function, inflammation, and gastrointestinal integrity were highlighted as contributors to obesity among PLHIV. Fibrotic subcutaneous adipose tissue is metabolically dysfunctional and loses its capacity to expand, leading to fat redistribution, including visceral obesity and ectopic fat accumulation, promoting insulin resistance. Viral proteins, including viral protein R and negative regulatory factor, have effects on adipogenic pathways and cellular metabolism in resident macrophages and T cells. HIV also affects immune cell trafficking into the adipose compartments, with effects on adipogenesis, lipolysis, and ectopic fat accumulation. Key cellular metabolic functions are likely to be affected in PLHIV by gut-derived cytokines and altered microbiota. There are limited strategies to reduce obesity specifically in PLHIV. Enhancing our understanding of critical pathogenic mechanisms will enable the development of novel therapeutics that may normalize adipose tissue function and distribution, reduce inflammation, and improve insulin sensitivity in PLHIV. Abstract : This review describes immunopathogenic mechanisms leading to obesity in individuals living with HIV, with a view to therapeutic interventions.